Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
6 studies found for:    21449783 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Active, not recruiting Comparison of Two Triple Regimens for Treatment and Retreatment of Chronic Hepatitis C Infection
Condition: Hepatitis C Infection
Intervention:
2 Not yet recruiting A Pilot Study of Boceprevir for the Treatment of Genotype 6 HCV
Condition: Chronic Hepatitis C
Interventions: Drug: Victrelis® (boceprevir) 800mg by mouth, TID (200 mg tablets);   Drug: Peg-Intron® (peginterferon-α-2b), 1.5ug/kg sc injection;   Drug: Rebetol® (ribavirin), 1000/1200mg by mouth daily
3 Recruiting Comparative Effectiveness and Tolerability of Boceprevir vs Telaprevir
Conditions: Hepatitis C,;   Cirrhosis
Interventions: Drug: Telaprevir;   Drug: Boceprevir;   Drug: Peg-IFN;   Drug: Ribavirin
4 Not yet recruiting Study of Combining Boceprevir With Peginterferon Alfa-2b and Ribavirin in the Treatment-naive Patients Infected With Genotype 4 Chronic Hepatitis C Infection
Condition: Genotype 4 Chronic Hepatitis C Infection
Interventions: Drug: Boceprevir;   Drug: Peginterferon alfa-2b;   Drug: ribavirin
5 Recruiting Real-life Security and Efficacy of DAA-based Therapy in HCV/HIV-Coinfected Patients
Conditions: Hepatitis C, Chronic;   Human Immunodeficiency Virus
Intervention: Drug: DAA against HCV
6 Completed
Has Results
Safety and Efficacy of Boceprevir in Previously Untreated Subjects With Chronic Hepatitis C Genotype 1 (Study P05216AM2) (COMPLETED)
Condition: Hepatitis C, Chronic
Interventions: Biological: Peginterferon alfa-2b (PEG);   Drug: Ribavirin (RBV);   Drug: Placebo;   Drug: Boceprevir

Indicates status has not been verified in more than two years